603538.SS SHH
Ningbo Menovo Pharmaceutical Co., Ltd.
1W: -0.8%
1M: +8.1%
3M: +2.1%
YTD: +33.6%
1Y: +9.7%
3Y: +55.8%
5Y: -7.1%
¥28.59 ($4.26)
+2.60 (+10.00%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$1.4B
+12.9% ▲
5Y CAGR: +3.1%
Gross Profit
$448M
+30.6% ▲
5Y CAGR: -0.2%
Operating Income
$93M
+393.9% ▲
5Y CAGR: -13.4%
Net Income
$67M
+476.6% ▲
5Y CAGR: -15.0%
EPS (Diluted)
$0.31
+520.0% ▲
5Y CAGR: -15.7%
EBITDA
$269M
+73.1% ▲
5Y CAGR: -0.2%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.5B | $1.2B | $1.4B |
| YoY Growth | +1.1% | +5.4% | +15.8% | -16.5% | +12.9% |
| Cost of Revenue | $759M | $789M | $873M | $874M | $925M |
| Gross Profit | $435M | $469M | $584M | $343M | $448M |
| Gross Margin | 36.5% | 37.3% | 40.1% | 28.2% | 32.6% |
| R&D Expenses | $62M | $88M | $98M | $95M | $100M |
| SG&A Expenses | $64M | $82M | $127M | $89M | $98M |
| Operating Expenses | $236M | $281M | $341M | $324M | $355M |
| Operating Income | $216M | $188M | $405M | $19M | $93M |
| Operating Margin | 18.1% | 14.9% | 27.8% | 1.5% | 6.7% |
| Interest Expense | $26M | $28M | $28M | $30M | $49M |
| Income Before Tax | $215M | $180M | $384M | $8M | $87M |
| Tax Expense | $42M | $22M | $17M | -$8M | $11M |
| Net Income | $156M | $143M | $339M | $12M | $67M |
| Net Margin | 13.1% | 11.3% | 23.3% | 1.0% | 4.9% |
| EPS (Diluted) | $0.76 | $0.66 | $1.49 | $0.05 | $0.31 |
| EBITDA | $321M | $302M | $498M | $155M | $269M |
| Shares Outstanding | 206M | 216M | 227M | 232M | 213M |